Bank of America
EPRX

Bank of America’s Eupraxia Pharmaceuticals EPRX Stock Holding History

Bank of America’s Portfolio EPRX Stock Details EPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.75M Sell
264,721
-3,500
-1% -$24.1K ﹤0.01% 4299
2026
Q1 		$1.94M Buy
268,221
+14,900
+6% +$120K ﹤0.01% 4135
2025
Q4 		$1.91M Buy
253,321
+207,744
+456% +$1.28M ﹤0.01% 4101
2025
Q3 		$269K Buy
45,577
+33,018
+263% +$180K ﹤0.01% 6135
2025
Q2 		$72.3K Buy
12,559
+10,059
+402% +$38.6K ﹤0.01% 6662
2025
Q1 		$8.2K Buy
+2,500
New +$8.63K ﹤0.01% 7148

Other funds holding EPRX

BGC
Beutel, Goodman & Co Toronto, Ontario, Canada $13.6B AUM 17.82% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
SC
Scotia Capital Toronto, Ontario, Canada $26.8B AUM 33.07% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Bank of America's EPRX Position: Q2 2026 in Review

Bank of America reduced its Eupraxia Pharmaceuticals (EPRX) stake by 1.3% in Q2 2026, selling an estimated $24.1K and leaving 264,721 shares worth $1.75M. The position accounts for ﹤0.01% of the portfolio, ranked #4299.

Bank of America first reported a position in EPRX in Q1 2025 and has held it in 6 quarters since. The position peaked at $1.94M in Q1 2026. 67 funds tracked by Wall St. Rank hold EPRX as of Q2 2026.

  • Bank of America held 264,721 shares of Eupraxia Pharmaceuticals worth $1.75M as of Q2 2026.
  • Bank of America sold 3,500 Eupraxia Pharmaceuticals shares in Q2 2026, an estimated $24.1K.
  • Eupraxia Pharmaceuticals made up ﹤0.01% of Bank of America's portfolio in Q2 2026, its #4299 holding.
  • Bank of America first reported a position in Eupraxia Pharmaceuticals in Q1 2025 and has held it in 6 quarters since.
  • Bank of America's Eupraxia Pharmaceuticals position peaked at $1.94M in Q1 2026.
  • 67 funds tracked by Wall St. Rank held Eupraxia Pharmaceuticals as of Q2 2026.

Based on Bank of America's 13F filing for Q2 2026, filed 14 Aug 2026.